Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. — ME/CFS Atlas
E2 ModeratePreliminaryPEM not requiredCross-SectionalPeer-reviewedReviewed
Standard · 3 min
Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness.
Maes, Michael, Mihaylova, Ivanka, Kubera, Marta et al. · Neuro endocrinology letters · 2009
Quick Summary
This study found that people with depression have lower levels of Coenzyme Q10 (CoQ10), a natural substance in the body that helps protect cells from damage, compared to healthy people. The researchers discovered that people with depression who don't respond well to treatment and those with chronic fatigue had even lower CoQ10 levels. This suggests that CoQ10 might play a role in why some people with depression feel persistently tired and why depression can increase heart disease risk.
Why It Matters
For ME/CFS patients, this finding is significant because it identifies a potential biological marker—low CoQ10—that may explain both the treatment resistance seen in some depression cases and the persistent fatigue accompanying depression. Since CoQ10 is an antioxidant involved in energy production and cardiovascular protection, understanding its role could inform targeted interventions and explain why depressed ME/CFS patients face elevated cardiovascular risk.
Observed Findings
Plasma CoQ10 was significantly lower in depressed patients than healthy controls (p=0.0002).
51.4% of depressed patients had CoQ10 levels below the lowest value observed in any control subject.
Patients with treatment-resistant depression had lower CoQ10 than other depressed patients.
Patients with chronic fatigue syndrome comorbid with depression had lower CoQ10 than depressed patients without CFS.
No significant correlation was found between CoQ10 levels and depression severity as measured by the Hamilton Depression Rating Scale.
Inferred Conclusions
Low CoQ10 plays a pathophysiological role in depression, particularly in treatment-resistant depression and depression accompanied by chronic fatigue.
Low CoQ10 may contribute to increased cardiovascular disease risk in depressed patients, providing a mechanistic link between depression and heart disease.
Depressed patients, especially those with treatment-resistant depression and CFS, may benefit from CoQ10 supplementation.
Remaining Questions
Does CoQ10 supplementation improve depression symptoms, fatigue, or treatment response in depressed patients and those with comorbid CFS?
Is low CoQ10 a pre-existing risk factor that predisposes to depression and CFS, or does it develop secondary to these conditions?
What This Study Does Not Prove
This study does not prove that low CoQ10 causes depression or ME/CFS; it only shows an association. The cross-sectional design cannot establish whether low CoQ10 precedes illness onset or develops as a consequence of depression. The study also does not demonstrate that CoQ10 supplementation would improve depression or fatigue symptoms, only that it may be beneficial based on CoQ10's known biological properties.
Tags
Symptom:Fatigue
Biomarker:MetabolomicsBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.